title: Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.
authors.forename: C
authors.initials: C
authors.lastname: Schützinger
authors.forename: A
authors.initials: A
authors.lastname: Gaiger
authors.forename: R
authors.initials: R
authors.lastname: Thalhammer
authors.forename: M
authors.initials: M
authors.lastname: Vesely
authors.forename: R
authors.initials: R
authors.lastname: Fritsche-Polanz
authors.forename: I
authors.initials: I
authors.lastname: Schwarzinger
authors.forename: L
authors.initials: L
authors.lastname: Ohler
authors.forename: I
authors.initials: I
authors.lastname: Simonitsch-Klupp
authors.forename: F
authors.initials: F
authors.lastname: Reinhard
authors.forename: U
authors.initials: U
authors.lastname: Jäger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019676:Genes, T-Cell Receptor delta; D019675:Genes, T-Cell Receptor gamma; D006801:Humans; D015458:Leukemia, T-Cell / Q000150:complications*; D008297:Male; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab